TABLE 2.
Fusion inhibition by antienvelope MAbs to parental and frameshift envelopes
| Envelopea | Mean ± SEM % inhibition of fusion by MAbb:
|
|
|---|---|---|
| 2G12 (complex) | 1331A (C5) | |
| 8x | 41 ± 7 | 31 ± 2 |
| HXB | 1 ± 15 | 31 ± 4 |
| HXB/FS | 52 ± 1 | 41 ± 3 |
| UGO-24 | 19 ± 10 | 29 ± 8 |
| UGO-24/FS | 42 ± 6 | 8 ± 3 |
| JRFL | 7 ± 7 | 45 ± 3 |
| JRFL/FS | 60 ± 4 | 52 ± 5 |
| ADA | 43 ± 8 | 22 ± 12 |
| ADA/FS | 36 ± 6 | 26 ± 3 |
| ADA-CD4i | 34 ± 9 | 42 ± 3 |
| ADA-CD4i/FS | 67 ± 3 | 58 ± 2 |
a
/FS, containing FS.
b
Material in parentheses indicates regions for which MAbs are specific. MAbs were used at 2.5 μg/ml. Significantly different data are shown in bold. The data are normalized to the amount of inhibition obtained with human immunoglobulins. The data are representative of at least three experiments done in triplicate.